Business
ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of 28th U.S. Patent
ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the
About this update from Endra Life Sciences Inc.
[{"type":"text","content":" ANN ARBOR, Mich.--(BUSINESS WIRE)--\nENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the ‘272 patent) titled “Broadband Applicator for Thermoacoustic Signal Generation.”\n\nThe ‘272 patent protects TAEUS’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. Notably, the RF applicator utilizes a broad bandwidth, which reduces TAEUS’ sensitivity to tissue variation and temperature. The ‘272 patent will serve as the parent patent for future patent applications prosecuted in China and Europe.\n\n“We are pleased with the issuance of our 28th patent in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs,” stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. “We continue to strengthen our intellectual property (IP) portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 48 patents issued globally.”\n\nAbout ENDRA Life Sciences Inc.\n\nENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.\n\nForward-Looking Statements\n\nAll statements in this press release that are not based on historical fact are \"forward-looking statements\" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-lo...